Dysmetabolic iron overload syndrome (DIOS).
Dysmetabolic iron overload syndrome (DIOS). Presse Med. 2017 Nov 20;: Authors: Deugnier Y, Bardou-Jacquet É, Lainé F Abstract Dysmetabolic iron overload syndrome (DIOS) corresponds to mild increase in both liver and body iron stores associated with various components of metabolic syndrome in the absence of any identifiable cause of iron excess. It is characterized by hyperferritinemia with normal or moderately increased transferrin saturation, one or several metabolic abnormalities (increased body mass index with android distribution of fat, elevated blood pressure, dyslipidaemia, abnormal glucose metabolism, steatohepatitis), and mild hepatic iron excess at magnetic resonance imaging or liver biopsy. Alteration of iron metabolism in DIOS likely results from a multifactorial and dynamic process triggered by an excessively rich diet, facilitated by environmental and genetic cofactors and implying a cross-talk between the liver and visceral adipose tissue. Phlebotomy therapy cannot be currently considered as a valuable option in DIOS patients. Sustained modification of diet and life-style habits remains the first therapeutic intervention in these patients together with drug control of increased blood pressure, abnormal blood glucose and dyslipidaemia when necessary. PMID: 29169710 [PubMed - as supplied by publisher]
DiscussionThis review will be the first to report and summarise the risk for and incidence of PPC in adult patients with MetS undergoing surgery across a range of surgical specialities. The results have the potential to inform the development of evidenced-based interventions to improve the management of PPC in the surgical patient with MetS. Findings from this systematic review and meta-analysis will inform a subsequent Delphi study on priorities and responses to PPC in patients with MetS. We will also disseminate our results through publication in scientific peer-reviewed journals, conference presentations and promotion t...
Limiting food consumption to a 10-hour window a day, so-called time-restricted eating, promotes weight loss and improves lipids/blood pressure in patients with metabolic syndrome.Medscape Medical News
Time-restricted eating, a form of intermittent fasting, appears to benefit people with metabolic syndrome, who are at a higher risk of diabetes, heart disease, and stroke.
This study does not go into detail about the extent to which these comorbidities may influence the increased risk of cancer in psoriasis patients. People with severe psoriasis often do not get enough relief with topical therapies (ones applied to the skin), such as topical corticosteroids and vitamin D analogues. They may then be started on medications that target specific immune cells and proteins. Some of these medications increase the risk of infections. Previous studies have found little to no increased risk of cancer in patients receiving these therapies. Other treatments, such as phototherapy (light therapy), are kno...
(University of California - San Diego) Researchers from University of California San Diego School of Medicine and the Salk Institute for Biological Studies reported a form of intermittent fasting, called time-restricted eating, improved the health of study participants who had been diagnosed with metabolic syndrome.
by Thomas M. McGrath, Eleanor Spreckley, Aina Fernandez Rodriguez, Carlo Viscomi, Amin Alamshah, Elina Akalestou, Kevin G. Murphy, Nick S. Jones Better understanding of feeding behaviour will be vital in reducing obesity and metabolic syndrome, but we lack a standard model that captures the complexity of feeding behaviour. We construct an accurate stochastic model of rodent feeding at the bout level in order to perform quantitative behavio ural analysis. Analysing the different effects on feeding behaviour of peptide YY3-36 (PYY3-36), lithium chloride, glucagon-like peptide 1 (GLP-1), and leptin shows the precise behaviou...
ConclusionsCompared to other pituitary adenomas, secreting and non-secreting, where pituitary surgery is the recommended first-line treatment, men with prolactinomas will usually respond to medical treatment with no need for any additional treatment.